Novavax (NVAX) Research & Development (2010 - 2026)

Novavax's Research & Development history runs 17 years deep, the most recent figure standing at $95.5 million for Q1 2026.

• In Q1 2026, Research & Development rose 7.35% year-over-year to $95.5 million; the TTM figure through Mar 2026 stood at $348.9 million (down 9.96% YoY), while the FY2025 annual figure was $342.3 million, down 12.49% from the prior year.
• Research & Development was $95.5 million for Q1 2026 at Novavax, up from $75.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $383.5 million in Q1 2022 to a low of $75.9 million in Q4 2025.
• Historically, Research & Development has averaged $164.8 million across 5 years, with a median of $106.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Research & Development tumbled 73.22% in 2022, then rose 12.75% in 2025.
• A 5-year view of Research & Development shows it stood at $257.8 million in 2022, then tumbled by 36.13% to $164.7 million in 2023, then tumbled by 36.62% to $104.4 million in 2024, then decreased by 27.31% to $75.9 million in 2025, then climbed by 25.83% to $95.5 million in 2026.
• The last three Research & Development figures came in at $95.5 million (Q1 2026), $75.9 million (Q4 2025), and $98.3 million (Q3 2025), per Business Quant data.